Viridian Therapeutics Inc Forecast, price target & analysts
Viridian Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Viridian Therapeutics Inc Classifications & Recommendation
Viridian Therapeutics Inc Price Target
| Target Price | $35.70 |
| Price | $20.47 |
| Potential |
74.40%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Viridian Therapeutics Inc 2027 .
The average Viridian Therapeutics Inc target price is $35.70.
This is
74.40%
register free of charge
$52.50
156.47%
register free of charge
$22.22
8.55%
register free of charge
|
|
| A rating was issued by 23 analysts: 22 Analysts recommend Viridian Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Viridian Therapeutics Inc stock has an average upside potential 2027 of
74.40%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 70.85 | 28.48 |
| 23,516.67% | 59.80% | |
| EBITDA Margin | -457.90% | -1,565.88% |
| 99.54% | 241.97% | |
| Net Margin | -483.56% | -1,532.37% |
| 99.46% | 216.90% |
17 Analysts have issued a sales forecast Viridian Therapeutics Inc 2026 . The average Viridian Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Viridian Therapeutics Inc EBITDA forecast 2026. The average Viridian Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Viridian Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Viridian Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.04 | -3.85 |
| 1.51% | 4.70% | |
| P/E | negative | |
| EV/Sales | 56.99 |
17 Analysts have issued a Viridian Therapeutics Inc forecast for earnings per share. The average Viridian Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Viridian Therapeutics Inc...
Current Viridian Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jun 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
